Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
Lapatinib
71
CHF
CHF 71.00
In stock
SYN-1052-M0011 mgCHF 71.00
SYN-1052-M0055 mgCHF 85.00
SYN-1052-M01010 mgCHF 99.00
SYN-1052-M05050 mgCHF 270.00
SYN-1052-M100100 mgCHF 383.00
| Product Details | |
|---|---|
| Synonyms | GW-572016 |
| Product Type | Chemical |
| Properties | |
| Formula | C29H26ClFN4O4S |
| MW | 581.1 |
| CAS | 231277-92-2 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO or ethanol. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: EGFR | Kinase Group: RTK | Substrate: Tyrosine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | BCFGMOOMADDAQU-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
Lapatinib is an ATP-competitive epidermal growth factor receptor (EGFR) and HER2/neu (ErbB-2) dual tyrosine kinase inhibitor, with IC(50) values of 10.8 and 9.2nM respectively. It is an orally active drug for treatment of breast cancer and other solid tumors.
Product References
- Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways: W. Xia, et al.; Oncogene 21, 6255 (2002)
Related Products
